Power3 Investors Looking Forward to Expo (OTC:PWRM)

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the opening bell on heavy buying pressure. The spark which ignited the rise in share price is being speculated as being attributed due to the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 19-21, 2009, of which Power3 Medical will be attending. Excitement over the company is building, as they will now be exposed to over 50,000 scientists worldwide. Volume at the end of day was 21.62M as compared to the daily average of 2.6M.

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. In the area of neurodegenerative diseases and breast cancer, Power3 has completed research and clinical validation studies involving over 1,500 patient samples. Power3 uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company has discovered protein biomarker patterns in over 1,500 patient samples that cover a range of diseases.
Company Updates

They have recently filed for 3 utility patents due to their advances in early stage breast cancer research and are expecting to complete phase II clinical validation trials of their blood serum diagnostics for Alzheimer’s and Parkinson’s disease (NuroPro AD and PD), in the fourth quarter of 2009, followed by completion of filing with the FDA. The medical testing industry is huge and extremely profitable.

Proteomics is the study and analysis of proteins, the fundamental building blocks of the human body. By studying proteins, scientists can understand more fully the functioning of a healthy body and identify the proteins associated with specific diseases. Proteins are not only the building blocks for life; in them, evidence can be found for serious diseases such as cancer, neurodegenerative diseases and other life threatening diseases. The research platform is centered on the study of proteomics, the science of protein interactions within living cells. With a combined 50+ years of proteomic experience, the Company has identified 334 protein biomarkers with the following potential medical applications:

• Breast Cancer
• Alzheimer’s Disease
• ALS (Lou Gehrig’s Disease)
• Parkinson’s Disease
• Leukemia
• Gastrointestinal Disease
• Metabolic Syndrome
• Chemotherapeutic Drug Resistance

Upcoming Company News

PWRM Announced that its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and
Expo of Molecular Diagnostics in Beijing, China in November 2009.

Further international recognition of validity as the company’s President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote
address and chair a session on “Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),” at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership.”

Technical Analysis

For the past three months, Power3 Medical has spent time consolidating between 0.05 and the 0.10 price level. There seems to be strong support at 0.05, as well an equally strong resistance at 0.10, which the stock managed to break today for the 2nd time. The last time the 0.10 resistance was shattered was in mid-to-end September, around the time the company announced they would participate in the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009. Thus, it is without coincidence that the strong 0.10 resistance has once again been broken, just prior to the start of November 19th, when they are scheduled to present. The RSI should move past the 70 line within the coming days, with the MACD and EMA maintaining a strong bullish golden cross. Should tremendous buying pressure and excessive volume continue, a new 52wk high could be set as the stock surges onward towards the 0.16 resistance.

Disclosure: Long PWRM